Clinical TrialMajor Depressive Disorder (MDD)PlaceboKetamineCompleted

EEG Characteristics in ECT

Randomised, early-phase diagnostic parallel study (n=11) comparing ketamine versus methohexital induction during ECT, using dcEEG to examine infra-slow/slow-wave characteristics in patients with major depressive episodes.

Target Enrollment
11 participants
Study Type
Phase I interventional
Design
Randomized, double Blind

Detailed Description

This pilot, randomized parallel study uses direct current EEG to compare infra-slow wave activity in depressed patients receiving ECT with induction by ketamine versus methohexital.

The aim is to identify dcEEG biomarkers of treatment adequacy (infra-slow wave suppression) that could inform ECT dosing and reduce morbidity; outcomes include dcEEG metrics across sessions and clinical depression severity.

Study Arms & Interventions

Methohexital

active comparator

Standard of care anesthesia that does not affect slow wave characteristics

Interventions

  • Placebo
    via IV• single dose

    Methohexital induction agent

Ketamine

experimental

Induction agent that suppresses infra-slow waves

Interventions

  • Ketamine
    via IV• single dose

    Ketamine induction agent

Participants

Ages
18 – 65
Sexes
Male & Female

Inclusion Criteria

  • Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features);
  • The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response;
  • Hamilton Depression Rating Scale 24-item (HDRS-24) > 21;
  • Age range between 18 and 65 years of age.

Exclusion Criteria

  • Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness > 5 minutes, epilepsy, Alzheimer's disease);
  • Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder);
  • Current drug or alcohol use disorder, except for nicotine and marijuana;
  • Adults unable to consent, pregnant women, prisoners;
  • Non-English speakers;
  • Patients that cannot tolerate Methohexital and Ketamine.

Study Details

Locations

University of New Mexico Mental Health Center — Albuquerque, New Mexico, United States

Your Library